[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345089-105":59,"doc-detail-345089-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-broad-societal-value-of-pembrolizumab-for-womens-cancer-in-canada-research-article","The broad societal value of pembrolizumab for women’s cancer in Canada - Research Article","","The study evaluates how pembrolizumab’s value for women’s cancers expands beyond healthcare costs and clinical outcomes in a Canadian context. Net monetary benefit (NMB) is estimated for four cancers—early-stage and metastatic triple-negative breast cancer, microsatellite instability-high endometrial cancer, and cervical cancer—across payer, traditional societal, and broad societal perspectives. Broad societal framing yields a substantially higher NMB, with insurance value identified as a major driver. The findings indicate health technology assessments may undercapture societal therapeutic value.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-broad-societal-value-of-pembrolizumab-for-womens-cancer-in-canada-research-article/345089/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-broad-societal-value-of-pembrolizumab-for-womens-cancer-in-canada-research-article/345089.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about pembrolizumab’s value in Canada?","Question",{"text":112,"@type":113},"It assesses how the societal and economic value of pembrolizumab for women’s cancers changes when broader value elements are included beyond standard healthcare-system costs and outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which cancers and perspectives are included in the net monetary benefit analysis?",{"text":117,"@type":113},"The analysis covers early-stage and metastatic triple-negative breast cancer, MSI-high endometrial cancer, and cervical cancer, assessed from traditional payer, traditional societal, and broad societal perspectives.",{"name":119,"@type":110,"acceptedAnswer":120},"What major factor drives the study’s results for broad societal value?",{"text":121,"@type":113},"Including insurance value is identified as the largest driver of the overall net monetary benefit under the broad societal perspective.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345089,1790676936,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","FUTURE ONCOLOGY  \n2026, VOL. 22, NO. 8, 939–952  \n[https://doi.org/10.1080/14796694.2026.2639738](https://doi.org/10.1080/14796694.2026.2639738)  \n| RESEARCH ARTICLE   \u003Cbr>The broad societal value of pembrolizumab for women’s cancer in Canada\u003Cbr>Elizabeth Brook a, Karl Patterson b, Nishini Wijenayakeb, Matthew Madin-Warburtonb, Kathryn Mishkinc, MarieClaude Meilleurd, Annabelle Davies e and Kate Young c\u003Cbr>aHealth Economics and Outcomes Research, Inizio Ignite Putnam, London, UK; bHealth Economics and Outcomes Research, Lumanity, London, UK; cMerck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USA; dHealth Economics and Outcomes Research, Merck Canada Inc., Kirkland, QC, Canada; eMerck Research Laboratories, MSD (UK) Ltd., London, UK |  |  |\n| --- | --- | --- |\n| ABSTRACT\u003Cbr>Aims: The impact of women’s cancers is multifaceted, with broad societal and economic consequences. Health technology assessments often rely solely on costs and outcomes directly relevant to the healthcare system. Our study incorporates the additional and novel value elements across three perspectives for pembrolizumab in four women’s cancers in a Canadian setting.\u003Cbr>Patients and methods: We analyzed the net monetary benefit (NMB) of pembrolizumab-based treatments of early-stage triple-negative breast cancer, metastatic triple-negative breast cancer, microsatellite instability-high endometrial cancer, and cervical cancer from three perspectives: traditional payer perspective (TPP), traditional societal perspective (TSP), and broad societal perspective (BSP) . Indicationsand comparators were modeled independently, combined, and weighted by prevalence.\u003Cbr>Results: Pembrolizumab-based therapy generated an NMB over four times greater with the BSP (Canadian dollars, CAD$925,078), compared with TPP (CAD$226,090) and TSP (CAD$222,556) . The largest driver of results was the inclusion of insurance value. Results excluding insurance value still generated an NMB of CAD$484,384, more than twice the TPP.\u003Cbr>Conclusions: Broadening the perspective to include additional value elements considerably increased the overall value of treatment of women’s cancer compared with the TPP, indicating that the perspective used by health technology bodies may not fully capture the societal value of therapeutics.\u003Cbr>PLAIN LANGUAGE SUMMARY\u003Cbr>The Value Of Treating Women’s Cancers In Canada – Traditionally, when people decide if a new treatment is valuable, they look at how much it helps the patient and how much it costs. Other things like how the caregiver feels, lost income, and extra costs that patients pay themselves are usually not included. Pembrolizumab is a medicine used to treat some cancers. It is used to treat triple-negative breast cancer, cervical cancer, and endometrial cancer. This paper looks at how decision makers judge the value of pembrolizumab and offers a new model to demonstrate how treating women’s cancers may be valuable for society as a whole. |  | ARTICLE HISTORY\u003Cbr>Received 6 August 2025 Accepted 25 February 2026\u003Cbr>KEYWORDS\u003Cbr>Perspective; societal; health Economics; women’s health; health technology assessment |\n| 1. Introduction\u003Cbr>Globally, more than 2 million women per year are diagnosed with breast or gynecological cancers, with incidence rates continuing to rise [1]. Female breast cancer (BC) accounted for 11.6% of all cancers diagnosed in 2022 and was the second most common cancer worldwide [2,3]. BC is categorized into different subtypes, and of interest to this research is triple-negative breast cancer (TNBC), specifically early-stage triple-negative breast cancer (eTNBC) and metastatic triple-negative breast cancer (mTNBC). Gynecologic cancer consists of five main types of cancers that originate from a woman’s reproductive organs, including cervical cancer (CC) and endometrial cancer (EC). Globally, in 2022 CC and EC were the fourth and sixth most common cancers in women, respectively [4,5]. This study is conducted from a Canadian perspecti","cbCaipBgBwq02KFx","https://ap.wps.com/l/cbCaipBgBwq02KFx","pdf",2063537,14,"English","# Abstract\n## Patients and methods\n## Results\n## Conclusions\n# Plain language summary\n# Introduction","[{\"question\":\"What question does the study address about pembrolizumab’s value in Canada?\",\"answer\":\"It assesses how the societal and economic value of pembrolizumab for women’s cancers changes when broader value elements are included beyond standard healthcare-system costs and outcomes.\"},{\"question\":\"Which cancers and perspectives are included in the net monetary benefit analysis?\",\"answer\":\"The analysis covers early-stage and metastatic triple-negative breast cancer, MSI-high endometrial cancer, and cervical cancer, assessed from traditional payer, traditional societal, and broad societal perspectives.\"},{\"question\":\"What major factor drives the study’s results for broad societal value?\",\"answer\":\"Including insurance value is identified as the largest driver of the overall net monetary benefit under the broad societal perspective.\"}]","The broad societal value of pembrolizumab for women’s cancer in Canada - Research Article | PDF",1790056484,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6fa6e6e223badaa5a6465e0ff28b114.webp",983,1280,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4300873c64417f752680083ed017046b.webp",982,1278,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ab085e6a6243b42d61b531a6621f9ce.webp",981,1277,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05f208652c297f4e80c7eb4992399801.webp",980,1276]